Lipocine Inc.

LPCN Nasdaq SEC CIK 1535955
Follow Lipocine Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $190.1K −69.5% vs same quarter last year
Net income −$2.6M −18.9% vs same quarter last year
EPS, diluted −$0.32 +22% vs same quarter last year
Operating cash flow −$3M −60.6% vs same quarter last year
Revenue by quarter
$0
$3.5M
$93.9K
$622.8K
$114.6K
$1.1M
$119.4K
$190.1K
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$30M−$20M−$10M$0$10M$20MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$2M−$9.6M
FY24$11.2M$10K
FY23−$2.9M−$16.4M
FY22$500K−$10.8M
FY21$16.1M−$634.4K
FY20$0−$21M
FY19$165K−$13M
FY18$428K−$11.7M
FY17$0−$21M
FY16$0−$19M
FY15-−$18.2M
FY14-−$20.4M
FY13$0−$10.6M
FY12$7.7M$3.9M
FY11-−$5.2K
MarginsShare of revenue
  • Operating margin
  • Net margin
−8000%−6000%−4000%−2000%0%2000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−524.7%−487.2%
FY24−10.3%0.1%
FY23--
FY22−2423.9%−2151.7%
FY2119.5%−3.9%
FY20--
FY19−7818.8%−7883.7%
FY18−2646%−2724.1%
FY17--
FY16--
FY15--
FY14--
FY13--
FY1250.3%50.4%
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$20M−$15M−$10M−$5M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$1.3M
FY23−$11.9M
FY22−$12.1M
FY21−$4.4M
FY20-
FY19-
FY18−$12.1M
FY17−$16.7M
FY16−$18.3M
FY15−$15.4M
FY14−$17.4M
FY13−$8.6M
FY12−$3.2M
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Lipocine
  • Healthcare median
−8000%−6000%−4000%−2000%0%2000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearLipocineHealthcare median
FY25−487.2%−40.6%
FY240.1%−60.7%
FY23-−97.1%
FY22−2151.7%−128.5%
FY21−3.9%−129.2%
FY20-−136.5%
FY19−7883.7%−133.7%
FY18−2724.1%−173.4%
FY17-−176.7%
FY16-−164.8%
FY15-−183.4%
FY14-−133%
FY13-−88.5%
FY1250.4%−87.4%
FY11-−76.3%

News

No stories filed under Lipocine yet - coverage appears here as the news feed clusters it.